BlueWillow Biologics, Inc.
BlueWillow is a clinical-stage biotech company focused on developing intranasal allergy & infectious disease vaccines using its patented NanoVax® platform
BlueWillow is an emerging biotech company that is entering a very exciting time. We have exclusive rights to a proprietary nanotechnology that was discovered at the University of Michigan. We have received $70M in NIH & Gates grants to develop an intranasal NanoVax® platform for infectious disease and allergy vaccines. We are raising a $3M round to accelerate development of our peanut allergy vaccine, while NIH supports our other key programs.